Overview Financials News + Filings Key Docs Charts Ownership Insiders |
Guardant Health, Inc. (GH)
|
Add to portfolio |
|
|
Price: |
$97.98
| | Metrics |
OS: |
117.7
|
M
| |
|
|
Market cap: |
$11.5
|
B
| |
|
|
Net cash:
|
$86.2
|
M
| |
$0.73
|
per share
|
EV:
|
$11.4
|
B
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
|
| |
|
|
EBIT
|
|
| |
|
|
EPS |
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
Revenues | 449.5 | 373.7 | 286.7 | 214.4 | 90.6 | 49.8 | 25.2 |
Revenue growth | 20.3% | 30.3% | 33.8% | 136.5% | 81.9% | 97.4% | |
Cost of goods sold | 156.3 | 122.9 | 92.5 | 70.7 | 43.2 | 31.6 | 22.1 |
Gross profit | 293.2 | 250.7 | 194.2 | 143.7 | 47.4 | 18.2 | 3.1 |
Gross margin | 65.2% | 67.1% | 67.7% | 67.0% | 52.3% | 36.6% | 12.4% |
Sales and marketing | 299.8 | 191.9 | 106.5 | 78.3 | 53.5 | 32.5 | 26.2 |
Research and development | 373.8 | 263.2 | 149.9 | 86.3 | 50.7 | 25.6 | 10.9 |
General and administrative | 164.0 | 206.6 | 192.8 | 61.4 | 36.2 | 36.8 | 9.9 |
EBITA | -541.9 | -409.1 | -253.2 | -81.7 | -92.9 | -76.6 | -43.8 |
EBITA margin | -120.5% | -109.5% | -88.3% | -38.1% | -102.5% | -153.7% | -173.7% |
Amortization of intangibles | 2.5 | 1.9 | 1.8 | 0.7 | | | |
EBIT | -544.4 | -411.0 | -255.0 | -82.4 | -92.9 | -76.6 | -43.8 |
EBIT margin | -121.1% | -110.0% | -88.9% | -38.4% | -102.5% | -153.7% | -173.7% |
Pre-tax income | -653.4 | -384.5 | -245.9 | -69.7 | -84.2 | -83.2 | -46.1 |
Income taxes | 1.1 | 0.3 | 0.4 | -1.9 | 0.0 | 0.0 | 0.0 |
Tax rate | | | | 2.7% | | | |
Net income | -654.6 | -405.7 | -253.8 | -75.7 | -85.1 | -89.0 | -46.1 |
Net margin | -145.6% | -108.6% | -88.5% | -35.3% | -93.8% | -178.6% | -182.7% |
|
Diluted EPS | ($6.41) | ($4.00) | ($2.60) | ($0.84) | ($2.80) | ($7.07) | ($3.53) |
Shares outstanding (diluted) | 102.2 | 101.3 | 97.5 | 90.6 | 30.4 | 12.6 | 13.1 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|